Short-term Efficacy and Safety of HepaSphere Drug-loaded Microsphere Embolization on Primary Hepatocellular Carcinoma

Objective To evaluate the short-term clinical efficacy and safety of transcatheter arterial chemoembolization using HepaSphere microsphere in the treatment of primary hepatocellular carcinoma with HepaSphere microspheres.

Methods We retrospectively analyzed 58 patients with hepatocellular carcinoma treated with HepaSphere microspheres (loaded with pirarubicin) from June 2015 to July 2017. We compared the local tumor response by CT or MR. The postoperative complications and liver function changes were compared by relevant examination results and clinical symptoms.

Results The liver function showed a transient change after TACE. Postoperative complications were acceptable and could be alleviated after symptomatic support. The average postoperative hospital stay was 1.72 days. According to the mRECIST criteria, the objective response rates (CR+PR) were 81.0%, 75.9%, 65.5%, and the disease control rates (CR+PR+SD) were 96.6%, 93.1%, 87.9% at 1, 3, 6 months after treatment. The one-year survival rate was 93.1%.

Conclusion The short-term clinical efficacy and safety of transarterial chemoembolisation using HepaSphere microspheres on unresectable hepatocellular carcinoma are acceptable.